Prepare for up to a Dozen Humira Biosimilars

November 2022

Up to 12 biosimilars for Humira (adalimumab) are slated to hit the market in 2023...starting with Amjevita in January.

This is a big deal. Humira is approved for several indications...rheumatoid arthritis, plaque psoriasis, Crohn’s, etc.

Plus it’s a top seller...annual revenue is over $20 billion.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter membership benefits include:

12 issues every year — what you need to know and do, right now
Quick, practical reference charts and tools
Comprehensive CE library to meet license renewal and state requirements
Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote